Graybug LLC
Graybug LLC is listed today as CalciMedica, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2023 | $9 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Jul 2019 | $55 M | No. 4 | $50 to $250 million | equity | SEC | |
| Apr 2016 | $75 M | No. 3 | $50 to $250 million | equity | SEC | |
| Feb 2015 | $2 M | No. 2 | Under $2 million | equity, options | SEC | |
| Sep 2013 | $1 M | No. 1 | Under $2 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Graybug LLC chose not to state its revenue in its newest notice of a funding round (Apr 2023).
SEC Form D · Apr 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2023
That is all the official record says: Graybug LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Graybug LLC are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Blackstone Clarus III L.L.C. | Other | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Group Management L.L.C. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Holdings I/II GP Inc | Company | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Holdings II L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Inc. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Clarus Lifesciences III, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Clarus Ventures III GP, L.P. | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Healthcare Innovations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt HIF, L.P | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Gerald D. Cagle | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding CalciMedica, Inc. shares, as of Sep 30, 2026.
- Woodline Partners LP$1 M7.22%
- Armistice Capital, LLC$1 M5.64%
- Stonepine Capital Management, LLC$0 M4.04%
- Stempoint Capital LP$0 M3.61%
- Heights Capital Management, Inc$0 M2.37%
- Renaissance Technologies LLC$0 M0.70%
- Geode Capital Management, LLC$0 M0.37%
- Cambridge Investment Research Advisors, Inc.$0 M0.24%
- Jane Street Group, LLC$0 M0.22%
- Rockefeller Capital Management L.P.$0 M0.06%
- Tower Research Capital LLC (TRC)$0 M0.04%
- Jpmorgan Chase & Co$0 M0.04%
- Brown Brothers Harriman & Co$0 M0.00%
- Osaic Holdings, Inc.$0 M0.00%
- SBI Securities Co., Ltd.$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| A. Rachel Leheny | Executive officer | Apr 2023 |
| Daniel J. Geffken | Executive officer | Apr 2023 |
| Eric W. Roberts | Executive officer | Apr 2023 |
| Kenneth A. Stauderman | Executive officer | Apr 2023 |
| Michael J. Dunn | Executive officer | Apr 2023 |
| Sudarshan J. Hebbar | Executive officer | Apr 2023 |
| Frederic Guerard | Executive officer | Aug 2019 |
| Pamela Michael Wapnick | Executive officer | Aug 2019 |
| Jeffrey Cleland | Executive officer | Jun 2018 |
| Jeffrey L. Cleland | Executive officer | May 2016 |
| Michael O'Rourke | Executive officer | Mar 2015 |
| Christy Wyskiel | Executive officer | Oct 2013 |
| Justin Hanes | Executive officer | Oct 2013 |
| A. Rachel Leheny | Director | Apr 2023 |
| Allan N. Shaw | Director | Apr 2023 |
| Eric N. Bjerkholt | Director | Apr 2023 |
| Eric W. Roberts | Director | Apr 2023 |
| Fred N. Middleton | Director | Apr 2023 |
| Frederic N. Guerard | Director | Apr 2023 |
| Robert N. Wilson | Director | Apr 2023 |
| Cameron Wheeler, Ph.D. | Director | Aug 2019 |
| Chau Khuong | Director | Aug 2019 |
| Christy Shaffer, Ph.D. | Director | Aug 2019 |
| Emmett Cunningham, M.D., Ph.D. | Director | Aug 2019 |
| Frederic Guerard | Director | Aug 2019 |
| Gerald Cagle, Ph.D. | Director | Aug 2019 |
| Hansoo Michael Keyoung | Director | Aug 2019 |
| Cameron Wheeler | Director | Jun 2018 |
| Chau Khoung | Director | Jun 2018 |
| Christy Shaffer | Director | Jun 2018 |
| Emmett Cunningham | Director | Jun 2018 |
| Gerald Cagle | Director | Jun 2018 |
| Jeffrey Cleland | Director | Jun 2018 |
| Justin Hanes | Director | Jun 2018 |
| Christy L. Shaffer | Director | May 2016 |
| Gerald L. Cagle | Director | May 2016 |
| Jeffrey L. Cleland | Director | May 2016 |
| Justin L. Hanes | Director | May 2016 |
| Michael O'Rourke | Director | Mar 2015 |
| Frederic Guerard | Promoter | Aug 2019 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.